SAN DIEGO, April 7 /PRNewswire-FirstCall/ -- Protein Polymer Technologies,
Inc. (OTC Bulletin Board: PPTI), reported today that, in an effort to protect
its shareholders, it has initiated actions for an immediate de-listing of its
common stock from the Borse-Berlin-Bremen Stock Exchange (the "BBBSE") in
Germany.  The Company recently learned that its common stock had been listed
for trading on the BBBSE without the Company's prior knowledge, consent or
authorization.  The Company is seeking to be de-listed because it is concerned
that the price of its common stock in the U.S. markets could be subject to
manipulation by trading practices permitted on the BBBSE which would not be
permitted in the U.S. markets.  Counsel to the Company has initiated
correspondence to the appropriate parties seeking immediate de-listing of the
Company's common stock from the BBBSE; however, since the Company's approval
of a listing on the BBBSE is not required, there can be no assurance that
these efforts will be successful.  Investors looking to purchase shares of the
Company should only purchase their shares from authorized broker-dealers who
will execute trades on the Over-The-Counter Bulletin Board under the stock
symbol PPTI.
    Separately, the Company reported that it intends to pursue a listing of
its common stock on the American Stock Exchange.  The Company has not yet made
application to the AMEX and there can be no assurance that the AMEX will
approve the Company's application when filed.

    Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes.  From its
inception in 1988, PPTI has been a pioneer in protein design and synthesis,
creating an extensive portfolio of proprietary biomaterials for use in the
development of bioactive devices.  These genetically engineered biomaterials
are high molecular weight proteins, processed into products with physical and
biological characteristics tailored to specific clinical performance
requirements.  Targeted products include urethral bulking agents for the
treatment of stress urinary incontinence, dermal augmentation products for
cosmetic and reconstructive surgery, surgical adhesives and sealants,
scaffolds for wound healing and tissue engineering, and depots for local drug
delivery.  To date, PPTI has been issued twenty-six U.S. Patents on its core
technology with corresponding issued and pending patents in key international
markets.

    This press release contains forward-looking statements that are based on
management's views and expectations.  Actual results could differ materially
from those expressed here; further, the Company is not obligated to comment
specifically on those differences.  Risks associated with the Company's
activities include raising adequate capital to continue operations, scientific
and clinical product development uncertainties, competitive products and
approaches, continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale-up.  The reader is
encouraged to refer to the Company's 2004 Annual Report on Form 10-KSB, the
Company's quarterly reports on Form 10QSB, and other recent filings with the
Securities and Exchange Commission, copies of which are available from the
Company, to further ascertain the risks associated with the above statements.

Link to this page: